Technical Analysis for CALT - Calliditas Therapeutics AB

Grade Last Price % Change Price Change
F 32.92 4.24% 1.34
CALT closed up 4.24 percent on Friday, January 22, 2021, on 27 percent of normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Flat Up
Historical CALT trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Crossed Above 20 DMA Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Fell Below 20 DMA Bearish 4.24%
Narrow Range Bar Range Contraction 0.55%
Crossed Above 20 DMA Bullish 0.98%
Gapped Up Strength 0.98%
Oversold Stochastic Weakness 0.98%
Oversold Stochastic Weakness 9.37%
Slingshot Bearish Bearish Swing Setup 5.75%
Older End-of-Day Signals for CALT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
50 DMA Resistance about 4 hours ago
Rose Above 20 DMA about 6 hours ago
20 DMA Support about 6 hours ago
60 Minute Opening Range Breakout about 6 hours ago
Rose Above Previous Day's High about 6 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Calliditas Therapeutics AB Description

Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pharmaceutical Industry Pharmaceutical Products Pharmacy Medication Health Sciences Kidney Disease Kidney Diseases Renal Disease Iga Nephropathy Pharmaceutics

Is CALT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 38.0
52 Week Low 19.0
Average Volume 23,704
200-Day Moving Average 0.00
50-Day Moving Average 33.06
20-Day Moving Average 32.16
10-Day Moving Average 31.43
Average True Range 1.09
ADX 17.94
+DI 27.38
-DI 25.86
Chandelier Exit (Long, 3 ATRs ) 30.98
Chandelier Exit (Short, 3 ATRs ) 33.27
Upper Bollinger Band 34.43
Lower Bollinger Band 29.89
Percent B (%b) 0.67
BandWidth 14.12
MACD Line -0.24
MACD Signal Line -0.31
MACD Histogram 0.0704
Fundamentals Value
Market Cap 822.04 Million
Num Shares 25 Million
EPS -1.19
Price-to-Earnings (P/E) Ratio -27.58
Price-to-Sales 239.56
Price-to-Book 5.18
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 35.31
Resistance 3 (R3) 35.13 34.15 34.91
Resistance 2 (R2) 34.15 33.55 34.24 34.77
Resistance 1 (R1) 33.54 33.17 33.85 33.72 34.64
Pivot Point 32.56 32.56 32.72 32.65 32.56
Support 1 (S1) 31.95 31.96 32.26 32.13 31.20
Support 2 (S2) 30.97 31.58 31.06 31.07
Support 3 (S3) 30.36 30.97 30.93
Support 4 (S4) 30.54